Ignet

Gene Information

Gene symbol: MAGEA12

Gene name:

HGNC ID:

Related Genes

#	Gene Symbol	Number of hits
1	CTAG1B	1 hits
2	GAGE1	1 hits
3	HLA-C	1 hits
4	IFNG	1 hits
5	MAGEA1	1 hits
6	MAGEA10	1 hits
7	MAGEA2	1 hits
8	MAGEA3	1 hits
9	MAGEA4	1 hits
10	MAGEA6	1 hits
11	MAGEA8	1 hits
12	MAGEA9	1 hits
13	MAGEC2	1 hits
14	SILV	1 hits

Related Sentences

#	PMID	Sentence
1	11519046	In this study we document the surfacing of systemic immune reactivity toward a cryptic epitope from the MAGE-12 gene (MAGE-12:170-178), after temporary regression of a single melanoma metastasis, in response to gp100/PMel17-specific vaccination.
2	11519046	Surfacing of MAGE-12 specificity occurred in association with loss of gp100/PMel 17 targeted by the vaccine.
3	11519046	In this study we document the surfacing of systemic immune reactivity toward a cryptic epitope from the MAGE-12 gene (MAGE-12:170-178), after temporary regression of a single melanoma metastasis, in response to gp100/PMel17-specific vaccination.
4	11519046	Surfacing of MAGE-12 specificity occurred in association with loss of gp100/PMel 17 targeted by the vaccine.
5	12673681	Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178.
6	12673681	Patients with metastatic melanoma who expressed HLA-Cw*0702 and whose tumors had demonstrable MAGE-A12 expression were immunized with the peptide MAGE-A12:170-178 administered subcutaneously in incomplete Freund's adjuvant (IFA).
7	12673681	Nine patients were selected for vaccination based on MAGE-A12 expression and the presence of HLA-Cw*0702.
8	12673681	The immune response was monitored both by tetrameric HLA-Cw*0702/MAGE-A12:170-178 complexes and by analysis of interferon-gamma mRNA transcription using a quantitative real-time polymerase chain reaction assay after peptide-specific stimulation.
9	12673681	Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178.
10	12673681	Patients with metastatic melanoma who expressed HLA-Cw*0702 and whose tumors had demonstrable MAGE-A12 expression were immunized with the peptide MAGE-A12:170-178 administered subcutaneously in incomplete Freund's adjuvant (IFA).
11	12673681	Nine patients were selected for vaccination based on MAGE-A12 expression and the presence of HLA-Cw*0702.
12	12673681	The immune response was monitored both by tetrameric HLA-Cw*0702/MAGE-A12:170-178 complexes and by analysis of interferon-gamma mRNA transcription using a quantitative real-time polymerase chain reaction assay after peptide-specific stimulation.
13	12673681	Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178.
14	12673681	Patients with metastatic melanoma who expressed HLA-Cw*0702 and whose tumors had demonstrable MAGE-A12 expression were immunized with the peptide MAGE-A12:170-178 administered subcutaneously in incomplete Freund's adjuvant (IFA).
15	12673681	Nine patients were selected for vaccination based on MAGE-A12 expression and the presence of HLA-Cw*0702.
16	12673681	The immune response was monitored both by tetrameric HLA-Cw*0702/MAGE-A12:170-178 complexes and by analysis of interferon-gamma mRNA transcription using a quantitative real-time polymerase chain reaction assay after peptide-specific stimulation.
17	12673681	Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178.
18	12673681	Patients with metastatic melanoma who expressed HLA-Cw*0702 and whose tumors had demonstrable MAGE-A12 expression were immunized with the peptide MAGE-A12:170-178 administered subcutaneously in incomplete Freund's adjuvant (IFA).
19	12673681	Nine patients were selected for vaccination based on MAGE-A12 expression and the presence of HLA-Cw*0702.
20	12673681	The immune response was monitored both by tetrameric HLA-Cw*0702/MAGE-A12:170-178 complexes and by analysis of interferon-gamma mRNA transcription using a quantitative real-time polymerase chain reaction assay after peptide-specific stimulation.
21	12817001	A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.
22	12817001	We report here the identification of a new MAGE-3 peptide, which is recognized by three different CD4(+) T cell clones isolated from a melanoma patient vaccinated with a MAGE-3 protein.
23	12817001	These clones, which express different TCRs, recognize an HLA-DR1 peptide ACYEFLWGPRALVETS, which corresponds to the MAGE-3(267-282) and the MAGE-12(267-282) protein sequences.
24	12817001	One of the T cell clones, which expresses LFA-1 at a high level, lysed tumor cells expressing DR1 and MAGE-3.
25	12817001	Another of these DR1-restricted CD4(+) clones recognized not only the MAGE-3/12 peptide but also homologous peptides encoded by genes MAGE-1, 2, 4, 6, 10, and 11.
26	18398575	Real Time PCR was used to quantify the expression of genes MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MAGE-C2, NY-ESO-1 and GAGE-1,2,8 in 50 pediatric brain tumors of different histological subtypes.
27	23377668	The TCR used in this study recognized epitopes in MAGE-A3/A9/A12.
28	23377668	Molecular assays of human brain samples using real-time quantitative-polymerase chain reaction, Nanostring quantitation, and deep-sequencing indicated that MAGE-A12 was expressed in human brain (and possibly MAGE-A1, MAGE-A8, and MAGE-A9).